CVHealthcare · Medical Devices

CV Stock Forecast: CapsoVision, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026

$6.00

+1.52% on the day

The 1 Wall Street analysts covering CapsoVision, Inc. hold a median 12-month price target of $10 — +66.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 20 of 100 as at 22 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap

$301.3M

Ticker Nerd rank

20 / 100

Median analyst target

$10

Analysts covering

Total return, dividends reinvested

−7.1%

−14.5%

YTD

−43.9%

+50.8%

From 52W high

−58.4%

From 52W low

+68.5%

$14

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

CV stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores CapsoVision, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026

20 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Issuance

Momentum

Accruals

Revisions

Value

Volatility

Quality

Growth

Size (62): Smaller than most of the companies we track.

Growth (8): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CV stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CV, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says1 analysts

1 Buy0 Hold0 Sell

Low $10Median $10High $10

The green dot is the last close — the median target sits +66.7% from it.

Recent analyst actionsNewest first

Date	Firm	Action	Rating	Target
27 Mar 2026	Benchmark	Maintains	Speculative Buy	$14 → $10
31 Dec 2025	Benchmark	Maintains	Speculative Buy	—
28 July 2025	Benchmark	Initiates	Speculative Buy	—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CV appears on the weeks it earns a place.

Estimates

CV analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year

Analysts raising

Analysts cutting

Fundamentals

CapsoVision, Inc. (CV) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −5.8×
Price / sales: 21.7×
Price / book: 22.9×
EV / EBITDA: −9.9×

Growth & margins

Revenue growth (YoY): 9.9%
Earnings growth (YoY): —
Gross margin: 47.6%
Operating margin: −208.1%
Net margin: −214.7%

Returns & dividend

Return on equity: −335.1%
Return on assets: −132.5%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

CV vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices

Company	Market cap	TKN rank
CVCapsoVision, Inc.	$301.3M	20
RCELAVITA Medical, Inc.	$306.8M	63
TLSITriSalus Life Sciences, Inc.	$315.2M	29
TMCITreace Medical Concepts, Inc.	$276.5M	55
ELMDElectromed, Inc.	$329.0M	99
VMDViemed Healthcare, Inc.	$336.5M	96
LABStandard BioTools, Inc.	$261.0M	36

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own CapsoVision, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CV news & analysis

CapsoVision, Inc. (CV) Q2 2026 Earnings Call Transcript

Seeking Alpha · 14 Aug 2026neutral

Seeking Alpha published the transcript of CapsoVision, Inc.'s (CV) Q2 2026 earnings call. The item announces the availability of the transcript covering the company's quarterly earnings discussion, though no figures or details from the call are provided in this excerpt.

Why it matters — A CV watcher would care because the earnings call transcript is the primary source of management commentary and quarterly results for the company.

CapsoVision Q2 Earnings Call Highlights

MarketBeat · 13 Aug 2026positive

CapsoVision reported second-quarter revenue growth driven by increased sales of its CapsoCam Plus capsule endoscopy system. The company also advanced its artificial intelligence software rollout and development programs for colon and upper gastrointestinal applications.

Why it matters — The revenue growth and progress on AI software and expanded gastrointestinal applications signal continued execution on CapsoVision's core product strategy and pipeline.

CapsoVision Reports Second Quarter 2026 Financial Results

GlobeNewsWire · 13 Aug 2026neutral

CapsoVision, Inc. reported its second quarter 2026 financial results and provided a business update for the period ended June 30, 2026. The company, a commercial-stage developer of advanced imaging and AI-enabled capsule endoscopy solutions, made the announcement on August 13, 2026.

Why it matters — A CV watcher would care because quarterly financial results and the accompanying business update offer the latest picture of CapsoVision's operational and commercial performance.

CapsoVision® Announces International Launch of AI Highlights

GlobeNewsWire · 3 Aug 2026positive

CapsoVision announced the international launch of its AI Highlights feature, an AI-assisted review tool designed to support physician review of small bowel capsule endoscopy studies using the CapsoCam Plus system.

Why it matters — The international rollout of an AI-assisted review feature expands the capabilities of CapsoVision's CapsoCam Plus product in the capsule endoscopy market.

CapsoVision to Release Second Quarter 2026 Financial Results on August 13, 2026

GlobeNewsWire · 30 July 2026neutral

CapsoVision announced it will release its second quarter 2026 financial results on August 13, 2026, after market close. The company develops advanced imaging and AI-enabled capsule endoscopy solutions.

Why it matters — This is a standard earnings release announcement that will provide the latest financial performance data for CapsoVision.

FAQ

Frequently asked questions about CV stock

What is the CV stock price forecast for 2026-2027?

The 1 Wall Street analysts covering CapsoVision, Inc. have a median 12-month price target of $10, with estimates ranging from $10 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CV stock a buy right now?

Of the 1 analysts covering CapsoVision, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks CapsoVision, Inc. 20 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CV?

As at 22 Aug 2026, CapsoVision, Inc. ranks 20 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (62 of 100).

Will CV stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +66.7% from the last close, and Ticker Nerd's factor model ranks CapsoVision, Inc. 20 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CV stock forecast for 2030?

No analyst covering CapsoVision, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CV are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $10 over the next 12 months.

How has CV stock performed over the past year?

CapsoVision, Inc. returned +50.8% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does CapsoVision, Inc. do?

CapsoVision, Inc. is a commercial-stage medical technology company specializing in advanced imaging and artificial intelligence technologies for endoscopy solutions.

What is the latest news on CV?

The most recent item we track (Seeking Alpha, 14 Aug 2026): "CapsoVision, Inc. (CV) Q2 2026 Earnings Call Transcript". Seeking Alpha published the transcript of CapsoVision, Inc.'s (CV) Q2 2026 earnings call. The item announces the availability of the transcript covering the company's quarterly earnings discussion, though no figures or details from the call are provided in this excerpt.

Company

About CapsoVision, Inc.

CapsoVision, Inc. is a commercial-stage medical technology company specializing in advanced imaging and artificial intelligence technologies for endoscopy solutions. It focuses on identifying abnormalities in the gastrointestinal tract for diagnostic and screening purposes. The company's core product is the CapsoCam Plus, a single-use capsule endoscope system that provides panoramic visualization of the small-bowel mucosa to detect conditions such as obscure gastrointestinal bleeding and Crohn's disease. Additional offerings include CapsoCam Colon for colon visualization, polyp detection, and measurement, along with CapsoCloud, a cloud-based software-as-a-service platform for video access and download; CapsoAccess for capsule data management; CapsoView for video reading; and CapsoRetrieve, a retrieval kit using a magnetic wand. CapsoVision also provides capsule video reading services. These solutions serve gastrointestinal medical practices, clinics, and hospitals through distributor customers who resell the products. Founded in 2005 and headquartered in Saratoga, California, CapsoVision plays a key role in enhancing non-invasive diagnostic capabilities within the health technology sector.

CEO Mr. Kang-Huai Wang · 99 employees · United States · https://capsovision.com